Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genscript Biotech Corporation

https://www.genscript.com/

Latest From Genscript Biotech Corporation

US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Consumer Business Strategies

Legend Buyout Report Boosts, Validates China Biotech

A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.

China M & A

Bausch + Lomb’s Prescription For Consumer Health Sales Growth Includes ‘Benefit’ From Rx Drugs

Blink NutriTears supplement containing lutein/zeaxanthin, curcumin and vitamin D3 coming in 2024 is example of a cross-segment sales benefit B+L sees in dry eye product category. Consumer eye care and vision health product sales are key drivers for 18% Q1 net sales growth to $1.1bn.

Consumer Sales & Earnings

First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle

Canadian firm received approval from FDA for NDA submitted in May 2023 for Lumify Preservative Free. A month earlier, FDA approved Dr. Reddy's ANDA submitted in July 2021 for an equivalent of Lumify’s formulation, brimonidine tartrate 0.025% ophthalmic solution.

Prescription To OTC Switch Patents
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • CustomArray
    • Legend Biotech USA Inc.
    • Legend Biotech Ireland Limited
    • Nanjing GenScript Co Ltd
    • Nanjing Legend Biotechnology Co., Ltd.
    • GenScript ProBio
UsernamePublicRestriction

Register